STOCK TITAN
  1. Home
  2. News
  3. CANF

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.

The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.

Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.

Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.

This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.

News

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announces a patient treated with namodenoson in the Phase II Liver Cancer Study has achieved a complete response and 6.9 years overall survival. The FDA and EMA have approved a pivotal Phase III clinical study, enrolling patients in Israel, Europe, and the US. Namodenoson has Orphan Drug and Fast Track Status for the treatment of HCC. The market for HCC treatments is estimated to reach $3.8 billion by 2027 for the G8 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
none
-
News

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Rhea-AI Summary
Company management updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
none
-
News

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Rhea-AI Summary
Can-Fite BioPharma announced that the scientific journal Biomolecules published an article on the drug candidate namodenoson, highlighting its inhibition of pancreatic carcinoma growth and its mechanism of action. The company is developing an exploratory Phase II study to evaluate the safety and efficacy of namodenoson in treating patients with pancreatic carcinoma who failed first-line therapy. Namodenoson is also being evaluated in a Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
News

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

Rhea-AI Summary
Can-Fite BioPharma has entered into an agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI and ML techniques. The project aims to develop next-generation A3 adenosine receptor drug agonists that reduce development time and cost. Can-Fite will perform testing and validation of the drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
News

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

Rhea-AI Summary
Can-Fite BioPharma announces participation in BioJapan Conference for one-on-one meetings with Japanese companies specializing in Orphan Drugs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.48%
Tags
none
-
News

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

Rhea-AI Summary
Can-Fite BioPharma announces positive pre-clinical results for Namodenoson in inhibiting pancreatic carcinoma growth. Namodenoson showed significant growth inhibition and de-regulation of the Wnt and KRAS pathways responsible for the disease. Exploratory Phase II protocol for pancreatic carcinoma patients to be submitted for approval in Israel and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
none
News

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

Rhea-AI Summary
Can-Fite BioPharma CEO to present at H.C. Wainwright Conference, highlighting advanced stage pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
News

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Rhea-AI Summary
Can-Fite BioPharma announces financial results and clinical progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
earnings clinical trial
-
News

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

Rhea-AI Summary
Can-Fite signed an agreement with Fondazione Telethon for co-development of Piclidenoson for the treatment of Lowe Syndrome, estimated $100M market in the U.S. No drug available. FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
News

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Rhea-AI Summary
Can-Fite submits pediatric study plan for Piclidenoson to FDA for treatment of adolescents with psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is $1.48 as of December 20, 2024.

What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is approximately 8.8M.

What does Can-Fite BioPharma Ltd. specialize in?

Can-Fite BioPharma specializes in developing orally bioavailable small molecule therapeutic products for cancer, liver, and inflammatory diseases.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd. is headquartered at 10 Bareket Street, פ"ת, Israel.

What is Piclidenoson?

Piclidenoson is a drug candidate from Can-Fite BioPharma currently in Phase III clinical trials for treating psoriasis.

What is Namodenoson used for?

Namodenoson is aimed at treating liver conditions such as hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH).

What stage are the trials for Namodenoson?

Namodenoson is in a Phase III trial for HCC and a Phase IIb trial for NASH.

What is the A3 adenosine receptor (A3AR)?

The A3 adenosine receptor (A3AR) is a therapeutic target used by Can-Fite BioPharma's platform technology for drug development.

How does Can-Fite BioPharma's technology benefit patients?

Can-Fite BioPharma's technology focuses on developing oral therapeutics, which are easier to administer, potentially improving patient compliance and treatment outcomes.

What is the significance of Can-Fite BioPharma's partnerships?

Partnerships with research institutions and other entities help Can-Fite BioPharma advance its drug development programs and bring innovative therapies to market.

Is Can-Fite BioPharma listed on any stock exchange?

Yes, Can-Fite BioPharma Ltd. is listed on NASDAQ under the symbol CANF.

What is the focus of Can-Fite BioPharma's current projects?

The current focus includes advanced clinical trials for drugs treating psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).

Stock CANF logo
Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CANF Stock Data

8.84M
6.10M
10.5%
2.27%
Biotechnology
Healthcare
Link
United States of America
Ramat Gan